On Oct. 26, 2020, Bayer announced the acquisition of Asklepios BioPharmaceutical, a North Carolina-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas.

Bayer will pay an upfront consideration of $2 billion and potential success-based milestone payments of up to $2 billion.